Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial (Q40287703)
Jump to navigation
Jump to search
scientific article published on 7 May 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial |
scientific article published on 7 May 2012 |
Statements
1 reference
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial (English)
1 reference
Kathrin U Jansen
1 reference
Leszek Szenborn
1 reference
Jacek Wysocki
1 reference
Peter C Richmond
1 reference
Helen S Marshall
1 reference
Michael D Nissen
1 reference
Qin Jiang
1 reference
Maria Garcés-Sánchez
1 reference
Federico Martinón-Torres
1 reference
Johannes Beeslaar
1 reference
Joseph Eiden
1 reference
Shannon L Harris
1 reference
Thomas R Jones
1 reference
John L Perez
1 reference
2001 Study Investigators
1 reference
7 May 2012
1 reference
1 reference
Identifiers
1 reference